meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - triple negative
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
es-BC - TNBC - NA - all population
5
es-BC - TNBC - NA - PDL1 positive
1
es-BC - Triple negatif (TNBC) - 1st line (L1)
mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
mBC - Triple negative (TNBC) - 1st Line (L1)
1
mBC - TNBC - L1 - all population
7
mBC - TNBC - L1 - PDL1 positive
4
mBC-Triple negative (TNBC) - 2nd Line (L2)
3
mBC - TNBC - L2 - all population
2
mBC - TNBC - L2 - PDL1 positive
2
<span style="margin-left: 0em;">chemotherapy</span>
<span style="margin-left: 1em;">Standard of Care (SoC) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">pembrolizumab based treatment</span>
<span style="margin-left: 3em;">pembrolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (2)
progression or deaths (PFS) (2)
objective responses (ORR) (2)
DCR (2)
DOR (2)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
Evidence network for deaths_(OS)
2
KEYNOTE-119 (PDL1 CPS>1), 2019 KEYNOTE-119 (PDL1 CPS>10), 2019
Standard of Care (SoC)
pembrolizumab alone
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
Standard of Care (SoC)
pembrolizumab alone
Standard of Care (SoC)
---
NA
pembrolizumab alone
NA
---
pathologies: 240 - treatments: 359,575,577,576,869
result logic
×
Study list